The goal of this activity is to improve the knowledge and competence of learners in supporting prompt recognition, diagnosis, and management of patients with systemic mastocytosis.

This activity is intended for US-based physicians, including residents and fellows, physician associates, and nurse practitioners practicing in allergy/immunology and dermatology who care for patients with systemic mastocytosis.

This REMS-compliant dinner program is designed to enhance clinician confidence and competence in the safe and effective management of pain.

The PREPARE Summit program is an interactive, case-based educational series designed to help clinicians identify, evaluate, and manage early cognitive decline in primary care settings, led by experts in neurology, geriatrics, and primary care.

Systemic mastocytosis (SM) is a rare disease marked by abnormal mast cell accumulation in the skin & other organs. Join this live webinar to learn how to recognize SM in dermatology practice, improve diagnosis & referrals.

Systemic mastocytosis (SM) is a rare disease marked by abnormal mast cell accumulation in the skin & other organs. Join this live webinar to learn how to recognize SM in dermatology practice, improve diagnosis & referrals.

HER2 alterations are rare in NSCLC, but getting testing and treatment right is critical. Join this live, case-based webinar to learn when to test, explore new HER2-targeted therapies, & speed the path from detection to the right treatment.

Join us for a complimentary dinner and CME as our experts discuss the latest efficacy and safety data from clinical trials of newly approved and emerging therapies and new therapeutic combinations for small cell lung cancer (SCLC).

Join us for a complimentary dinner and CME as our experts discuss the latest efficacy and safety data from clinical trials of newly approved and emerging therapies and new therapeutic combinations for small cell lung cancer (SCLC).

Join us for a complimentary dinner and CME as our experts discuss the latest efficacy and safety data from clinical trials of newly approved and emerging therapies and new therapeutic combinations for small cell lung cancer (SCLC).